Shares of Mela Sciences Inc. (NASDAQ:SSKN) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Analysts have set a 12 month consensus price target of $2.00 for the company and are expecting that the company will post ($0.10) EPS for the current quarter, according to Zacks. Zacks has also given Mela Sciences an industry rank of 109 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research cut shares of Mela Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, June 11th.
An institutional investor recently raised its position in Mela Sciences stock. Sabby Management LLC raised its stake in shares of Mela Sciences Inc. (NASDAQ:SSKN) by 78.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,020,524 shares of the medical device company’s stock after buying an additional 447,447 shares during the period. Sabby Management LLC owned approximately 9.64% of Mela Sciences worth $623,000 as of its most recent SEC filing. 24.20% of the stock is currently owned by institutional investors and hedge funds.
Mela Sciences (NASDAQ:SSKN) opened at 0.54 on Monday. Mela Sciences has a 52-week low of $0.48 and a 52-week high of $1.53. The firm’s 50-day moving average is $0.57 and its 200 day moving average is $0.72. The stock’s market capitalization is $5.75 million.
Mela Sciences (NASDAQ:SSKN) last released its quarterly earnings results on Thursday, August 11th. The medical device company reported ($0.23) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by $0.13. Mela Sciences had a negative net margin of 32.47% and a negative return on equity of 2.84%. On average, equities analysts forecast that Mela Sciences will post ($0.27) earnings per share for the current year.
Mela Sciences Company Profile
STRATA Skin Sciences, Inc, formerly MELA Sciences, Inc, is a medical technology company. The Company is engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mela Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mela Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.